Active Biotech collaborates with Johns Hopkins University in Baltimore in the US with the aim of developing a drug for use in fighting prostate cancer. The collaboration has been successful and a final pharmaceutical candidate for clinical trials is expected to be selected shortly.
Next step in the project will be to prepare the process of large-scale production, followed by a more in-depth safety evaluation. This will be performed ahead of the clinical evaluation which is planned to begin during the first half of 2003.
The aim of the project is to develop a product with an anti-tumour effect based on the substance's ability to prevent blood supply (angiogenesis) to the tumour, thus cutting off the tumour's supply of nutrients and oxygen.
Prostate cancer is the most common form of cancer among men and accounts for almost one third of all cancers. The disease mainly affects men over 50 yeras of age. The severity of prostate cancer can vary considerably. Although the prognosis is relatively good, prostate cancer remains the form of cancer that causes most deaths among men in Sweden. The relative 10-year survival rate is around 50%.
Lund, 4 February 2002
Active Biotech AB (publ)
Sven Andréasson
President & CEO
Active Biotech is a biotechnology company focusing on research in and development of pharmaceuticals. Active Biotech has a strong R&D portfolio and pipeline products with focus primarily on autoimmune/inflammatory diseases and cancer. Most advanced projects (clinical trials phase II) include orally administered small molecules with unique immunomodulatory properties that can be used to treat autoimmune and inflammatory diseases(SAIK), as well as a novel concept for use in cancer immunotherapy(TTS).
Active Biotech AB
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 20 50
e-mail info@activebiotech.com